Fetal Defects in Mice Treated With Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir, and Cabotegravir.

Authors: Mohan H; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Nguyen J; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Yee A; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Laurette EY; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Sanghvi T; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Tejada O; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Jao J; Department of Pediatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Sled JG; Translational Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.; Mouse Imaging Center, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Greene NDE; Developmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom., Copp AJ; Developmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom., Serghides L; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.; Department of Immunology and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.

Source: The Journal of infectious diseases [J Infect Dis] 2025 Oct 15; Vol. 232 (4), pp. 847-858.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

MeSH Terms: Heterocyclic Compounds, 3-Ring*/adverse effects , Heterocyclic Compounds, 3-Ring*/administration & dosage , HIV Integrase Inhibitors*/adverse effects , Fetus*/abnormalities , Fetus*/drug effects , Abnormalities, Drug-Induced*, Animals ; Female ; Pyridones/adverse effects ; Pyridones/administration & dosage ; Piperazines ; Pregnancy ; Oxazines ; Raltegravir Potassium/adverse effects ; Raltegravir Potassium/administration & dosage ; Mice ; Mice, Inbred C57BL ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Amides ; Neural Tube Defects/chemically induced ; Diketopiperazines

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.

Authors: Trottier B; Département de Recherche, Clinique de Médecine Urbaine du Quartier Latin, Montreal, QC, Canada., Yang CJ; Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan., Watanabe D; AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan., Marchetti G; Department of Health Sciences, University of Milan, Milan, Italy., Elbirt D; Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., De Barra E; Department of International Health and Tropical Medicine, RCSI University of Medicine and Health Sciences, Beaumont Hospital, Dublin, Ireland., Gündüz A; Department of Infectious Diseases and Clinical Microbiology, Başakşehir Çam and Sakura City Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Lee SH; Department of Internal Medicine, Pusan National University School of Medicine and Pusan National University Hospital, Busan, Republic of Korea., Vogelmann R; Mannheimer Onkologie-Praxis, Mannheim, Germany.; Department of Medicine II, Medical Faculty Mannheim, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany., Robineau O; EA2694, University of Lille, Centre Hospitalier de Tourcoing, Tourcoing, France., Choy CY; Department of Infectious Diseases, National Centre for Infectious Diseases (NCID), Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore., Berrevoets M; Department of Internal Medicine and Infectious Diseases, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands., Uriel A; Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, UK., Thorpe D; Global HIV Medical Affairs, Gilead Sciences Europe Ltd, Uxbridge, UK., Heinzkill M; Medical Affairs, Gilead Sciences GmbH, Martinsried, Germany., Marongiu A; Real World Evidence, Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK., Ramroth J; Real World Evidence, Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK., D'Amato L; Clinical Operations, Gilead Sciences Srl, Milan, Italy., Mallolas J; HIV Unit, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.; Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Source: HIV research & clinical practice [HIV Res Clin Pract] 2025 Dec; Vol. 26 (1), pp. 2456890. Date of Electronic Publication: 2025 Feb 12.

Publication Type: Journal Article; Observational Study

Journal Info: Publisher: Taylor & Francis Group Country of Publication: England NLM ID: 101738312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2578-7470 (Electronic) Linking ISSN: 25787470 NLM ISO Abbreviation: HIV Res Clin Pract Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , HIV Infections*/immunology , Emtricitabine*/therapeutic use , Emtricitabine*/adverse effects , Emtricitabine*/administration & dosage , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/adverse effects , Tenofovir*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , Anti-HIV Agents*/administration & dosage , Adenine*/analogs & derivatives , Adenine*/therapeutic use , Adenine*/adverse effects , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/adverse effects , Heterocyclic Compounds, 4 or More Rings*/administration & dosage, Humans ; Male ; Female ; Adult ; Middle Aged ; Drug Combinations ; Alanine ; HIV-1/drug effects ; Pyridones ; Prospective Studies ; Treatment Outcome ; CD4 Lymphocyte Count ; Piperazines/therapeutic use ; Viral Load/drug effects ; Amides ; Heterocyclic Compounds, 3-Ring

A Robust and Accurate Filter Paper-Based Dried Plasma Spot Method for Bictegravir Monitoring in HIV Therapy.

Authors: Sathyanarayanan A; Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Udupi, Karnataka, India., Arekal RN; Department of Microbiology, Biotechnology and Food Technology, Bangalore University, Bengaluru, India., Somashekara D; Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Udupi, Karnataka, India.

Source: Rapid communications in mass spectrometry : RCM [Rapid Commun Mass Spectrom] 2025 Nov 15; Vol. 39 (21), pp. e10110.

Publication Type: Journal Article

Journal Info: Publisher: John Wiley And Sons Ltd Country of Publication: England NLM ID: 8802365 Publication Model: Print Cited Medium: Internet ISSN: 1097-0231 (Electronic) Linking ISSN: 09514198 NLM ISO Abbreviation: Rapid Commun Mass Spectrom Subsets: MEDLINE

MeSH Terms: Dried Blood Spot Testing*/methods , Drug Monitoring*/methods , HIV Infections*/drug therapy , HIV Infections*/blood , Heterocyclic Compounds, 4 or More Rings*/blood , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Anti-HIV Agents*/blood , Anti-HIV Agents*/therapeutic use, Humans ; Tandem Mass Spectrometry/methods ; Limit of Detection ; Reproducibility of Results ; Pyridones ; Chromatography, Liquid/methods ; Paper ; Linear Models ; Pyridazines ; Amides ; Heterocyclic Compounds, 3-Ring ; Piperazines

Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study.

Authors: Pérez-Valero I; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Corona Mata D; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Camacho Espejo A; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Gallo M; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., García-Ruiz de Morales AG; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Servicio de Enfermedades Infecciosas, Hospital Universitario Ramon y Cajal, Madrid, Spain.; Departamento de Medicina, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain., Fanciulli C; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Grupo de Microbiología Clínica, Enfermedades Infecciosas y SIDA, Instituto de Investigacion Sanitaria Gregorio Marañón, Madrid, Spain., Martín-Carbonero L; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Unidad de Enfermedades Infecciosas y VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, Spain.; Grupo de SIDA y Enfermedades Infecciosas, Instituto de Investigacion Biomedica Hospital La Paz, Madrid, Spain., Calzado Isbert S; Servei de Malalties Infeccioses, Parc Taulí Hospital Universitari, Barcelona, Spain.; Area de Infecciones e Inmunología, Institut d'Investigacio i Innovacio Parc Taulí, Barcelona, Spain.; Departament Medicina, Universitat Autonoma de Barcelona, Sabadell, Spain., Hernández Gutiérrez C; Unidad de Enfermedades Infecciosas, Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain., Asensi V; Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Oviedo, Spain., Rivero Juarez A; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Rivero A; Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Córdoba, Spain.; Grupo de Investigación en Virología Clínica y Zoonosis (GC26), Instituto Maimonides de Investigacion Biomedica de Córdoba, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina y Enfermeria, Universidad de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

Corporate Authors: Cohorte de la Red Española de Investigación en SIDA (CoRIS) Cohort

Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Nov 06; Vol. 81 (4), pp. e93-e101.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

MeSH Terms: Emtricitabine*/therapeutic use , Emtricitabine*/adverse effects , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/adverse effects , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , HIV Infections*/drug therapy , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/adverse effects , Adenine*/analogs & derivatives , Adenine*/therapeutic use , Adenine*/adverse effects, Humans ; Male ; Adult ; Female ; Middle Aged ; Alanine ; Pyridones ; Treatment Outcome ; Viral Load/drug effects ; Cohort Studies ; Piperazines ; CD4 Lymphocyte Count ; Drug Combinations ; Antiretroviral Therapy, Highly Active/methods ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Amides

Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways.

Authors: Arora P; Gilead Sciences, Inc., Foster City, CA, USA., Liu H; Gilead Sciences, Inc., Foster City, CA, USA., Ling J; Gilead Sciences, Inc., Foster City, CA, USA., Hindman JT; Gilead Sciences, Inc., Foster City, CA, USA., Marathe DD; Gilead Sciences, Inc., Foster City, CA, USA.

Source: Journal of clinical pharmacology [J Clin Pharmacol] 2025 Nov; Vol. 65 (11), pp. 1420-1432. Date of Electronic Publication: 2025 Jun 15.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

MeSH Terms: Glucuronosyltransferase*/antagonists & inhibitors , Glucuronosyltransferase*/metabolism , Heterocyclic Compounds, 4 or More Rings*/pharmacokinetics , Heterocyclic Compounds, 4 or More Rings*/pharmacology , Heterocyclic Compounds, 4 or More Rings*/administration & dosage , Heterocyclic Compounds, 4 or More Rings*/adverse effects , Cytochrome P-450 CYP3A*/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1*/antagonists & inhibitors , ATP Binding Cassette Transporter, Subfamily B, Member 1*/metabolism , Cytochrome P-450 CYP3A Inducers*/pharmacology , Cytochrome P-450 CYP3A Inhibitors*/pharmacology , Anti-HIV Agents*/pharmacokinetics, Humans ; Drug Interactions ; Adult ; Male ; Middle Aged ; Female ; Young Adult ; Adolescent ; Amides ; Heterocyclic Compounds, 3-Ring ; Piperazines ; Pyridones

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living with HIV Aged 50 Years and Older: A Retrospective Analysis of Naïve and Treatment-Experienced Individuals.

Authors: Trizzino M; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy., Pipitò L; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G D'Alessandro', University of Palermo, 90133 Palermo, Italy., Di Figlia F; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G D'Alessandro', University of Palermo, 90133 Palermo, Italy., Bonura S; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy., Zimmerhofer F; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G D'Alessandro', University of Palermo, 90133 Palermo, Italy., Cicero A; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G D'Alessandro', University of Palermo, 90133 Palermo, Italy., Gioè C; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy., Cascio A; Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico 'P. Giaccone', 90133 Palermo, Italy.; Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G D'Alessandro', University of Palermo, 90133 Palermo, Italy.

Source: Viruses [Viruses] 2025 Oct 31; Vol. 17 (11). Date of Electronic Publication: 2025 Oct 31.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , Emtricitabine*/therapeutic use , Emtricitabine*/adverse effects , Emtricitabine*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/adverse effects , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/adverse effects , Adenine*/analogs & derivatives , Adenine*/therapeutic use, Humans ; Middle Aged ; Male ; Retrospective Studies ; Female ; Aged ; HIV-1/drug effects ; Alanine ; Treatment Outcome ; Pyridones ; Viral Load/drug effects ; Piperazines/therapeutic use ; Drug Combinations ; CD4 Lymphocyte Count ; Amides ; Heterocyclic Compounds, 3-Ring

Population pharmacokinetics of bictegravir in real-world people with HIV.

Authors: Ekobena P; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Department of Otolaryngology and Head Neck Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Briki M; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Bio/CMOS Interfaces Laboratory, École Polytechnique Fédérale de Lausanne (EPFL), Neuchâtel, Switzerland., Dao K; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Marzolini C; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK., Andre P; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Buclin T; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Guidi M; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland., Thoueille P; Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Corporate Authors: Swiss HIV Cohort Study

Source: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2025 Oct 03; Vol. 80 (10), pp. 2782-2789.

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , Heterocyclic Compounds, 4 or More Rings*/pharmacokinetics , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , HIV Integrase Inhibitors*/pharmacokinetics , HIV Integrase Inhibitors*/therapeutic use , Pyridones*/pharmacokinetics, Humans ; Female ; Middle Aged ; Male ; Adult ; Drug Monitoring ; Switzerland ; Aged ; Amides/pharmacokinetics ; Aged, 80 and over ; Cohort Studies ; Young Adult ; Piperazines/pharmacokinetics ; Heterocyclic Compounds, 3-Ring

AI-driven discovery of antiretroviral drug bictegravir and etravirine as inhibitors against monkeypox and related poxviruses.

Authors: Wang Y; School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, China.; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Ünlü A; Biological Data Science Lab, Department of Computer Engineering, Hacettepe University, Ankara, Turkey.; Department of Bioinformatics, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey., Wang X; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Çevrim E; Biological Data Science Lab, Department of Computer Engineering, Hacettepe University, Ankara, Turkey.; Department of Bioinformatics, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey., Offermans DM; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Flesseman MP; Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, The Netherlands., Zaeck LM; Department of Viroscience, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Wu L; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Bijvelds MJC; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Sam-Agudu NA; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.; Department of Pediatrics and Child Health, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.; Global Pediatrics Program and Division of Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA., de Vries RD; Department of Viroscience, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Raymond K; Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, The Netherlands.; University of Grenoble Alpes, CEA, Inserm, IRIG, UA13 BGE, Biomics, Grenoble, France., Li P; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands., Olğaç A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey., Wang W; Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China. wenshi.wang@xzhmu.edu.cn., Doğan T; Biological Data Science Lab, Department of Computer Engineering, Hacettepe University, Ankara, Turkey. tuncadogan@gmail.com.; Department of Bioinformatics, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey. tuncadogan@gmail.com.; Department of Health Informatics, Institute of Informatics, Hacettepe University, Ankara, Turkey. tuncadogan@gmail.com., Pan Q; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands. q.pan@erasmusmc.nl.

Source: Communications biology [Commun Biol] 2025 Dec 02; Vol. 8 (1), pp. 1734. Date of Electronic Publication: 2025 Dec 02.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE

MeSH Terms: Pyridazines*/pharmacology , Pyrimidines*/pharmacology , Antiviral Agents*/pharmacology , Artificial Intelligence* , Drug Discovery*/methods , Monkeypox virus*/drug effects , Anti-Retroviral Agents*/pharmacology , Poxviridae*/drug effects , Heterocyclic Compounds, 4 or More Rings*/pharmacology , Mpox, Monkeypox*/drug therapy , Mpox, Monkeypox*/virology, Humans ; Nitriles/pharmacology ; Pyridones/pharmacology ; Animals ; Amides ; Heterocyclic Compounds, 3-Ring ; Piperazines

Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir.

Authors: Calcagno A; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Lipani C; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Rizzello B; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Mussa M; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Perinzano A; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Angilletta R; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Romano F; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Bosio R; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Allice T; Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASL 'Città di Torino'., Calitri C; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Guastamacchia G; Unit of Neurology, Ospedale Maria Vittoria, ASL 'Città di Torino', Turin, Italy., Trunfio M; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'.; HIV Neurobehavioral Research Program, Departments of Neurosciences and Psychiatry, University of California San Diego, San Diego, California, USA., Di Perri G; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'., Bonora S; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin and 'Amedeo di Savoia' Hospital, ASL 'Città di Torino'.

Source: AIDS (London, England) [AIDS] 2025 Dec 01; Vol. 39 (15), pp. 2250-2253. Date of Electronic Publication: 2025 Aug 11.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , HIV Infections*/pathology , Emtricitabine*/therapeutic use , Emtricitabine*/administration & dosage , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage , Cerebrospinal Fluid*/virology , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Medication Adherence*, Humans ; Female ; RNA, Viral/cerebrospinal fluid ; RNA, Viral/blood ; Viral Load ; Male ; Adult ; Middle Aged ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Alanine ; Drug Resistance, Viral ; High-Throughput Nucleotide Sequencing ; Amides ; Heterocyclic Compounds, 3-Ring ; Piperazines ; Pyridones

Noninvasive Evaluation of Trop2 Expression Using ⁶⁴ Cu-NOTA-Trodelvy-F(ab') 2 in Gastric and Pancreatic Cancer.

Authors: Huang W; Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.; Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States., Chao F; Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China., Li R; College of Letters and Science, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States., Yang Y; Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China., Hsu JC; Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States., DeLuca MC; Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States., Engle JW; Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States., Han X; Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China., Kang L; Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China., Cai W; Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States.

Source: Molecular pharmaceutics [Mol Pharm] 2025 Dec 01; Vol. 22 (12), pp. 7630-7640. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article

Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

MeSH Terms: Stomach Neoplasms*/metabolism , Stomach Neoplasms*/diagnostic imaging , Stomach Neoplasms*/pathology , Pancreatic Neoplasms*/metabolism , Pancreatic Neoplasms*/diagnostic imaging , Pancreatic Neoplasms*/pathology , Antigens, Neoplasm*/metabolism , Cell Adhesion Molecules*/metabolism , Copper Radioisotopes*/chemistry , Heterocyclic Compounds, 1-Ring*/chemistry , Immunoglobulin Fab Fragments*/chemistry, Humans ; Animals ; Mice ; Cell Line, Tumor ; Tissue Distribution ; Positron-Emission Tomography/methods ; Female ; Mice, Nude ; Xenograft Model Antitumor Assays ; Mice, Inbred BALB C ; Heterocyclic Compounds/chemistry

Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial).

Authors: Ambrosioni J; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jambrosioni@intramed.net., de Lazzari E; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Sánchez-Palomino S; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Bailón L; Department of Infectious Diseases and Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Suanzes P; Infectious Diseases Department, Hospital Universitario Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain., Busca C; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; HIV Unit, Hospital Universitario La Paz-Carlos III, IdiPAZ, Madrid, Spain., Ramos-Ruperto L; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; HIV Unit, Hospital Universitario La Paz-Carlos III, IdiPAZ, Madrid, Spain., Orviz E; Centro Sanitario Sandoval, Hospital Clínico San Carlos, IdISSC, Madrid, Spain., Rivero Á; Department of Infectious Diseases and Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; BCN Checkpoint, Barcelona, Spain., Mothe B; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases and Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; IrsiCaixa, Badalona, Spain; Department of Infectious Diseases and Immunity, University of Vic - Central University of Catalonia (UVic-UCC), Barcelona, Spain., Romero JD; Centro Sanitario Sandoval, Hospital Clínico San Carlos, IdISSC, Madrid, Spain., Falcó V; Infectious Diseases Department, Hospital Universitario Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain., Vicens-Artés S; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain., Moraga E; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain., Cruceta A; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain., Mallolas J; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Miró JM; HIV Unit, Hospital Clínic de Barcelona (HCB) - Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain. Electronic address: jmmiro@ub.edu.

Corporate Authors: BIC-PHI Study Group

Source: The Journal of infection [J Infect] 2025 Nov; Vol. 91 (5), pp. 106651. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , Emtricitabine*/therapeutic use , Emtricitabine*/adverse effects , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , Adenine*/analogs & derivatives , Adenine*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/therapeutic use, Humans ; Male ; Female ; Adult ; Viral Load/drug effects ; Pyridones/therapeutic use ; Alanine ; Piperazines/therapeutic use ; Treatment Outcome ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Drug Combinations ; HIV-1/drug effects ; Middle Aged ; Spain ; Amides

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study - IMEA 057.

Authors: Lê MP; AP-HP, Hospital Bichat-Claude Bernard, Pharmacology Laboratory, IAME UMR 1137 INSERM, Université Paris Cité, France. Electronic address: minh.le@aphp.fr., Allavena C; Hotel Dieu Hospital, Infectious and Tropical Diseases Department, Nantes, France., Joly V; AP-HP, Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases Department, IAME UMR 1137 INSERM, Université Paris Cité, France., Assoumou L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France., Isernia V; AP-HP, Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases Department, IAME UMR 1137 INSERM, Université Paris Cité, France., Ajana F; Gustave Dron Hospital, Infectious and tRopical Diseases Department, Tourcoing, France., Neau D; Pellegrin Hospital, Infectious and Tropical Diseases Department, Bordeaux, France., Descamps D; AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, IAME UMR 1137 INSERM, Université Paris Cité, Paris, France., Charpentier C; AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, IAME UMR 1137 INSERM, Université Paris Cité, Paris, France., Benalycherif A; IMEA, Hospital Bichat-Claude Bernard, Paris, France., Phung B; AP-HP, Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases Department, IAME UMR 1137 INSERM, Université Paris Cité, France., Peytavin G; AP-HP, Hospital Bichat-Claude Bernard, Pharmacology Laboratory, IAME UMR 1137 INSERM, Université Paris Cité, France., Landman R; AP-HP, Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases Department, IAME UMR 1137 INSERM, Université Paris Cité, France; IMEA, Hospital Bichat-Claude Bernard, Paris, France.

Corporate Authors: BICOLDER-IMEA 057 study group

Source: Journal of infection and public health [J Infect Public Health] 2025 Nov; Vol. 18 (11), pp. 102946. Date of Electronic Publication: 2025 Sep 01.

Publication Type: Clinical Study; Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101487384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-035X (Electronic) Linking ISSN: 18760341 NLM ISO Abbreviation: J Infect Public Health Subsets: MEDLINE

MeSH Terms: Adenine*/analogs & derivatives , Adenine*/therapeutic use , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , Drug Substitution* , Emtricitabine*/therapeutic use , Emtricitabine*/adverse effects , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , HIV Infections*/drug therapy , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/analogs & derivatives, Aged ; Female ; Humans ; Male ; Alanine ; Drug Combinations ; Drug Interactions ; HIV-1/drug effects ; Piperazines ; Prospective Studies ; Pyridones ; RNA, Viral/blood ; Treatment Outcome ; Viral Load ; Amides ; Heterocyclic Compounds, 3-Ring

Dihydroxanthene-Derived Dioxetane Chemiluminophores for Activatable in Vivo Imaging.

Authors: Liao K; School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China., Zhang L; School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China., Jiang J; School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China., Wang F; School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China., Peng T; School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China.; Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.

Source: Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2025 Oct 20; Vol. 64 (43), pp. e202514236. Date of Electronic Publication: 2025 Sep 01.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 0370543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-3773 (Electronic) Linking ISSN: 14337851 NLM ISO Abbreviation: Angew Chem Int Ed Engl Subsets: MEDLINE

MeSH Terms: Xanthenes*/chemistry , Luminescent Agents*/chemistry , Optical Imaging* , Heterocyclic Compounds*/chemistry, Animals ; Mice ; Humans ; Molecular Structure ; Heterocyclic Compounds, 1-Ring

Phenylamine-1,2-Dioxetanes: Promising Class of Chemiluminescent Luminophores for Aqueous Sensing and Bacterial Detection.

Authors: David M; School of Chemistry, Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv, 69978, Israel., Leirikh T; School of Chemistry, Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv, 69978, Israel., Naama N; School of Chemistry, Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv, 69978, Israel., Kopp T; School of Chemistry, Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv, 69978, Israel., Shabat D; School of Chemistry, Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv, 69978, Israel.

Source: Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2025 Oct; Vol. 64 (44), pp. e202515674. Date of Electronic Publication: 2025 Sep 06.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 0370543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-3773 (Electronic) Linking ISSN: 14337851 NLM ISO Abbreviation: Angew Chem Int Ed Engl Subsets: MEDLINE

MeSH Terms: Luminescent Measurements*/methods , Escherichia coli*/isolation & purification , Luminescent Agents*/chemistry , Heterocyclic Compounds*/chemistry, Water/chemistry ; Molecular Structure ; Luminescence ; Heterocyclic Compounds, 1-Ring

Perinatal and Early Infant Outcomes After Bictegravir Exposure in Pregnancy: A Canadian Surveillance Study.

Authors: Wong JMH; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Balleny R; Faculty of Medicine, University of British Columbia, Vancouver, Canada., Lee T; Centre for Advancing Health Outcomes, Vancouver, Canada., Bitnun A; Department of Pediatrics, University of Toronto, Toronto, Canada., Boucoiran I; Department of Obstetrics and Gynecology, Université de Montréal, Montréal, Canada., Brophy J; Department of Pediatrics, University of Ottawa, Ottawa, Canada., Comeau J; Department of Pediatrics, Dalhousie University, Halifax, Canada., Kakkar F; Department of Pediatrics, Université de Montréal, Montréal, Canada., McConnell A; Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada., Sauvé L; Department of Pediatrics, University of British Columbia, Vancouver, Canada., Singer J; CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research, Montréal, Canada; and., Tse-Chang A; Department of Pediatrics, University of Alberta, Edmonton, Canada., Money D; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.

Corporate Authors: Canadian Perinatal HIV Surveillance Program

Source: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2025 Oct 01; Vol. 100 (2), pp. 147-153.

Publication Type: Journal Article

Journal Info: Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 100892005 Publication Model: Print Cited Medium: Internet ISSN: 1944-7884 (Electronic) Linking ISSN: 15254135 NLM ISO Abbreviation: J Acquir Immune Defic Syndr Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/transmission , Pregnancy Complications, Infectious*/drug therapy , Pyridones*/therapeutic use , Anti-HIV Agents*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/therapeutic use, Humans ; Female ; Pregnancy ; Canada/epidemiology ; Infant, Newborn ; Adult ; Premature Birth/epidemiology ; Male ; Pregnancy Outcome ; Infectious Disease Transmission, Vertical/prevention & control ; Young Adult ; Infant ; Amides ; Heterocyclic Compounds, 3-Ring ; Piperazines

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Authors: Ryan P; Hospital Universitario Infanta Leonor, Madrid, Spain., Blanco JL; Hospital Clínic de Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Masia M; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital General Universitario, Elche, Spain., Garcia-Fraile L; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital Universitario de la Princesa, Madrid, Spain., Crusells MJ; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Domingo P; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Curran A; Hospital Universitari Vall d'Hebrón, Barcelona, Spain., Guerri-Fernandez R; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital del Mar, Barcelona, Spain., Bernal E; Hospital Reina Sofía, Murcia, Spain., Bravo J; Hospital Reina Sofía, Murcia, Spain., Revollo B; Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Macias J; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital Universitario Virgen de Valme, and IBiS-Universidad de Sevilla, Seville, Spain., Tiraboschi JM; Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain., Montejano R; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital Universitario La Paz, Madrid, Spain., Amador C; Hospital Marina Baixa, Villajoyosa, Spain., Torralba M; Hospital Universitario, Guadalajara, Spain., Merino D; Hospital Juan Ramón Jiménez, Huelva, Spain., Diaz-Brito V; Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Spain., Galindo MJ; Hospital Clínico Universitario, Valencia, Spain., Ferra S; Hospital Universitario Torrecárdenas, Almeria, Spain., Villoslada A; Hospital Universitario Son Llatzer, Palma de Mallorca, Spain., Losa JE; Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., Fanjul FJ; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Perez-Stachowski X; Hospital Costa del Sol, Marbella, Spain., Peraire J; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Hospital Universitari Joan XXIII, Tarragona, Spain., Portilla J; Hospital General Universitario Dr Balmis, Alicante, Spain., de la Fuente S; Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain., Dueñas C; Hospital Clínico, Valladolid, Spain., Vazquez MJ; ViiV Healthcare, Tres Cantos, Spain., Di Gregorio S; CP Endocrinologia i Nutrició SL, Barcelona, Spain., Esteban H; Fundación SEIMC-GeSIDA, Madrid, Spain., Gil P; Fundación SEIMC-GeSIDA, Madrid, Spain., de Miguel M; Fundación SEIMC-GeSIDA, Madrid, Spain., Alejos B; Madrid, Spain., Martínez E; Hospital Clínic de Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Reial Acadèmia de Medicina de Catalunya, Barcelona, Spain. Electronic address: estebanm@clinic.cat.

Corporate Authors: PASO-DOBLE study group

Source: The lancet. HIV [Lancet HIV] 2025 Jul; Vol. 12 (7), pp. e473-e484. Date of Electronic Publication: 2025 Jun 07.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Comparative Study; Equivalence Trial

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , Heterocyclic Compounds, 3-Ring*/therapeutic use , Heterocyclic Compounds, 3-Ring*/administration & dosage , Lamivudine*/therapeutic use , Lamivudine*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage, Humans ; Pyridones ; Male ; Female ; Piperazines/therapeutic use ; Adult ; Oxazines ; Emtricitabine/therapeutic use ; Emtricitabine/administration & dosage ; Middle Aged ; Tenofovir/therapeutic use ; Tenofovir/analogs & derivatives ; Tenofovir/administration & dosage ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; HIV-1/drug effects ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Alanine ; Viral Load/drug effects ; Amides ; Maintenance Chemotherapy/methods ; Spain ; Treatment Outcome ; Drug Therapy, Combination

MMP-9 inhibitor SB-3CT improves neurological outcomes in ischemic stroke mice by modulation of astrocytic lipid metabolism.

Authors: Du LD; Institute of Molecular Medicine & Innovative Pharmaceutics, Qingdao University, Qingdao, 266071, China.; Provincial Laboratory of Polymorphic Medicine, Tengzhou, 277599, China., Fang C; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China., Wang YQ; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.; University of Chinese Academy of Sciences, Beijing, 101408, China., Feng ZY; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China., Abiola OF; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China., Gao ZL; Provincial Laboratory of Polymorphic Medicine, Tengzhou, 277599, China., Huang JY; School of Pharmaceutical Sciences (Shenzhen). Sun Yat-sen University, Shenzhen, 518107, China. huangjuy5@mail.sysu.edu.cn., Ma YZ; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. yz.ma@siat.ac.cn.

Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2025 Aug; Vol. 46 (8), pp. 2120-2135. Date of Electronic Publication: 2025 Mar 11.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE

MeSH Terms: Astrocytes*/drug effects , Astrocytes*/metabolism , Lipid Metabolism*/drug effects , Ischemic Stroke*/drug therapy , Ischemic Stroke*/metabolism , Ischemic Stroke*/pathology , Matrix Metalloproteinase Inhibitors*/pharmacology , Matrix Metalloproteinase Inhibitors*/therapeutic use , Heterocyclic Compounds, 3-Ring*/pharmacology , Heterocyclic Compounds, 3-Ring*/therapeutic use , Neuroprotective Agents*/pharmacology , Neuroprotective Agents*/therapeutic use, Animals ; Male ; Mice ; Matrix Metalloproteinase 9/metabolism ; Mice, Inbred C57BL ; Disease Models, Animal ; Infarction, Middle Cerebral Artery/drug therapy ; Heterocyclic Compounds, 1-Ring ; Sulfones

Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial.

Authors: Sun HY; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Lin YT; School of Pharmacy, National Taiwan University College of Medicine, Taipei, Taiwan.; The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan., Chang WC; Department of Medical Research, The Tenth Core Lab, National Taiwan University, Taipei, Taiwan., Liu WC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Su YC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Kuo CH; School of Pharmacy, National Taiwan University College of Medicine, Taipei, Taiwan.; The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.; Department of Pharmacy, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Hung CC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.

Source: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2025 Aug 01; Vol. 80 (8), pp. 2179-2186.

Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , Emtricitabine*/administration & dosage , Emtricitabine*/therapeutic use , Anti-HIV Agents*/administration & dosage , Anti-HIV Agents*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/administration & dosage , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/administration & dosage , Tenofovir*/therapeutic use , Adenine*/analogs & derivatives , Adenine*/administration & dosage , Adenine*/therapeutic use, Humans ; Adult ; Male ; Female ; Middle Aged ; Pilot Projects ; Viral Load/drug effects ; Pyridones ; Piperazines ; Treatment Outcome ; Alanine ; HIV-1/drug effects ; Heterocyclic Compounds, 3-Ring ; RNA, Viral/blood ; Amides ; Carbamates ; Drug Combinations ; Young Adult

Bictegravir-emtrictabine-tenofovir alafenamide in combination with oxcarbazepine in a person living with HIV and viral load suppression.

Authors: Pecora Fulco P; Department of Internal Medicine/Division of Infectious Diseases/Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA, USA., Gray M; Division of Infectious Diseases, Virginia Commonwealth University Health, Richmond, VA, USA.

Source: International journal of STD & AIDS [Int J STD AIDS] 2025 Jul; Vol. 36 (8), pp. 664-666. Date of Electronic Publication: 2025 Apr 15.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Sage Country of Publication: England NLM ID: 9007917 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-1052 (Electronic) Linking ISSN: 09564624 NLM ISO Abbreviation: Int J STD AIDS Subsets: MEDLINE

MeSH Terms: Adenine*/analogs & derivatives , Adenine*/therapeutic use , Adenine*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage , Carbamazepine*/analogs & derivatives , Carbamazepine*/therapeutic use , Carbamazepine*/administration & dosage , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/administration & dosage , HIV Infections*/drug therapy , HIV Infections*/virology , Tenofovir*/analogs & derivatives , Tenofovir*/therapeutic use , Tenofovir*/administration & dosage , Tenofovir*/analogs & derivatives, Humans ; Alanine ; Amides ; Drug Therapy, Combination ; Emtricitabine/therapeutic use ; Oxcarbazepine/therapeutic use ; Piperazines ; Pyridones ; Treatment Outcome ; Viral Load/drug effects ; Heterocyclic Compounds, 3-Ring

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes.

Authors: Ghosn J; APHP.Nord, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses, Paris, France.; Université Paris Cité, INSERM UMR 1137 IAME, Paris, France., Chow J; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Gandhi M; University of California San Francisco, San Francisco, California, USA., Górgolas M; Fundación Jiménez Díaz, Madrid, Spain., Al-Hayani A; Fundación Jiménez Díaz, University Hospital, Madrid, Spain., Tookes H; University of Miami - Miller School of Medicine, Miami, Florida, USA., Lee M; Costello Medical, Boston, Massachusetts, USA., Kaiser EF; Costello Medical, Boston, Massachusetts, USA., Malebranche D; Gilead Sciences, Foster City, California, USA., Bognar FA; Gilead Sciences, Foster City, California, USA., Gandhi-Patel B; Gilead Sciences, Foster City, California, USA., Dai L; Beijing Youan Hospital, Capital Medical University, Beijing, China.

Source: HIV medicine [HIV Med] 2025 Sep; Vol. 26 (9), pp. 1375-1394. Date of Electronic Publication: 2025 Jun 26.

Publication Type: Journal Article; Systematic Review

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE

MeSH Terms: HIV Infections*/drug therapy , HIV Infections*/virology , Emtricitabine*/therapeutic use , Emtricitabine*/administration & dosage , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Tenofovir*/administration & dosage , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Adenine*/therapeutic use , Adenine*/analogs & derivatives, Humans ; HIV-1/drug effects ; Patient Reported Outcome Measures ; Pyridones/therapeutic use ; Drug Combinations ; Alanine ; Piperazines/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Treatment Outcome ; Viral Load ; Amides